Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zheming Ruan is active.

Publication


Featured researches published by Zheming Ruan.


Journal of Medicinal Chemistry | 2009

Discovery and Structure−Activity Relationships of Trisubstituted Pyrimidines/Pyridines as Novel Calcium-Sensing Receptor Antagonists

Wu Yang; Zheming Ruan; Yufeng Wang; Katy Van Kirk; Zhengping Ma; Brian J. Arey; Christopher B. Cooper; Ramakrishna Seethala; Jean H.M. Feyen; John K. Dickson

The trisubstituted pyrimidine 1 was identified through high-throughput screening as a novel calcium-sensing receptor (CaSR) antagonist. Small molecule CaSR antagonists and/or negative allosteric modulators have the potential to act as an anabolic agent for the treatment of osteoporosis. The investigation of structure-activity relationships around 1 resulted in the identification of 18c and 18d, which showed efficacy at promoting PTH release in vivo and exhibited improved potency and solubility over the original lead 1.


Bioorganic & Medicinal Chemistry Letters | 2008

Pyridine amides as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1

Haixia Wang; Zheming Ruan; James J. Li; Ligaya M. Simpkins; Rebecca A. Smirk; Shung C. Wu; Robert Hutchins; David S. Nirschl; Katy Van Kirk; Christopher B. Cooper; James C. Sutton; Zhengping Ma; Rajasree Golla; Ramakrishna Seethala; Mary Ellen K. Salyan; Akbar Nayeem; Stanley R. Krystek; Steven Sheriff; Daniel M. Camac; Paul E. Morin; Brian Carpenter; Jeffrey A. Robl; Robert Zahler; David A. Gordon; Lawrence G. Hamann

Several series of pyridine amides were identified as selective and potent 11beta-HSD1 inhibitors. The most potent inhibitors feature 2,6- or 3,5-disubstitution on the pyridine core. Various linkers (CH(2)SO(2), CH(2)S, CH(2)O, S, O, N, bond) between the distal aryl and central pyridyl groups are tolerated, and lipophilic amide groups are generally favored. On the distal aryl group, a number of substitutions are well tolerated. A crystal structure was obtained for a complex between 11beta-HSD1 and the most potent inhibitor in this series.


Bioorganic & Medicinal Chemistry Letters | 2011

Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.

Yan Shi; Stephen P. O'connor; Doree Sitkoff; Jing Zhang; Mengxiao Shi; Sharon N. Bisaha; Ying Wang; Chi Li; Zheming Ruan; R. Michael Lawrence; Herbert E. Klei; Kevin Kish; Eddie C.-K. Liu; Steve M. Seiler; Liang Schweizer; Thomas E. Steinbacher; William A. Schumacher; Jeffrey A. Robl; John E. Macor; Karnail S. Atwal; Philip D. Stein

The design, synthesis and SAR of a novel class of valerolactam-based arylsulfonamides as potent and selective FXa inhibitors is reported. The arylsulfonamide-valerolactam scaffold was derived based on the proposed bioisosterism to the arylcyanoguanidine-caprolactam core in known FXa inhibitors. The SAR study led to compound 46 as the most potent FXa inhibitor in this series, with an IC(50) of 7 nM and EC(2×PT) of 1.7 μM. The X-ray structure of compound 40 bound to FXa shows that the sulfonamide-valerolactam scaffold anchors the aryl group in the S1 and the novel acylcytisine pharmacophore in the S4 pockets.


Bioorganic & Medicinal Chemistry Letters | 2016

Discovery and SAR of pyrrolo[2,1-f][1,2,4]triazin-4-amines as potent and selective PI3Kδ inhibitors.

Rajeev S. Bhide; James Neels; Lan-Ying Qin; Zheming Ruan; Sylwia Stachura; Carolyn A. Weigelt; John S. Sack; Kevin Stefanski; Xiaomei Gu; Jenny Xie; Christine Goldstine; Stacey Skala; Donna L. Pedicord; Stefan Ruepp; T. G. Murali Dhar; Percy H. Carter; Luisa Salter-Cid; Michael A. Poss; Paul Davies

Aberrant Class I PI3K signaling is a key factor contributing to many immunological disorders and cancers. We have identified 4-amino pyrrolotriazine as a novel chemotype that selectively inhibits PI3Kδ signaling despite not binding to the specificity pocket of PI3Kδ isoform. Structure activity relationship (SAR) led to the identification of compound 30 that demonstrated efficacy in mouse Keyhole Limpet Hemocyanin (KLH) and collagen induced arthritis (CIA) models.


Bioorganic & Medicinal Chemistry Letters | 2017

Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors

Lan-Ying Qin; Zheming Ruan; Robert J. Cherney; T. G. Murali Dhar; James Neels; Carolyn A. Weigelt; John S. Sack; Anurag S. Srivastava; Lyndon A. M. Cornelius; Joseph A. Tino; Kevin Stefanski; Xiaomei Gu; Jenny Xie; Vojkan Susulic; Xiaoxia Yang; Melissa Yarde-Chinn; Stacey Skala; Ruth Bosnius; Christine Goldstein; Paul Davies; Stefan Ruepp; Luisa Salter-Cid; Rajeev S. Bhide; Michael A. Poss

As demonstrated in preclinical animal models, the disruption of PI3Kδ expression or its activity leads to a decrease in inflammatory and immune responses. Therefore, inhibition of PI3Kδ may provide an alternative treatment for autoimmune diseases, such as RA, SLE, and respiratory ailments. Herein, we disclose the identification of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent, selective and orally bioavailable PI3Kδ inhibitors. The lead compound demonstrated efficacy in an in vivo mouse KLH model.


ACS Combinatorial Science | 2009

Design and Synthesis of a G-Protein-Coupled Receptor Antagonist Library of Aryloxyalkanolamines Using a Polymer-Supported Acyclic Acetal Linker

Jacques Y. Roberge; Lalgudi S. Harikrishnan; Muthoni G. Kamau; Zheming Ruan; Katy Van Kirk; Yalei Liu; Christopher B. Cooper; Michael A. Poss; John K. Dickson; Ashvinikumar V. Gavai; Sam T. Chao; Leslie Leith; Mark S. Bednarz; Arvind Mathur; Ramesh Kakarla; Dora M. Schnur; Roy J. Vaz; R. Michael Lawrence

A G-Protein-coupled receptor-targeted library of aryloxypropanolamines and aryloxybutanolamines was efficiently executed using a novel, polymer-supported acyclic acetal linker, producing compounds in good yields and purities.


Bioorganic & Medicinal Chemistry Letters | 2017

Identification of highly potent and selective PI3Kδ inhibitors

David Marcoux; Lan-Ying Qin; Zheming Ruan; Qing Shi; Qian Ruan; Carolyn A. Weigelt; Hongchen Qiu; Gary L. Schieven; John Hynes; Rajeev S. Bhide; Michael A. Poss; Joseph A. Tino

Selective PI3Kδ inhibitors have recently been hypothesized to be appropriate immunosuppressive agents for the treatment of immunological disorders such as rheumatoid arthritis. However, few reports have highlighted molecules that are highly selective for PI3Kδ over the other PI3K isoforms. In this letter, isoform and kinome selective PI3Kδ inhibitors are presented. The Structural Activity Relationship leading to such molecules is outlined.


Bioorganic & Medicinal Chemistry Letters | 2009

Solid-phase synthesis of a library based on biphenyl-containing trypsin-like serine protease inhibitors

Shuhao Shi; Shirong Zhu; Samuel W. Gerritz; Bogumila Rachwal; Zheming Ruan; Robert Hutchins; Ramesh Kakarla; Michael J. Sofia; James C. Sutton; Daniel L. Cheney

The solid-phase synthesis of a library based on an unusual biphenyl-containing trypsin-like serine protease inhibitor is described. Key to this effort was the synthesis of a highly functionalized aryl boronic acid reagent which required the development of a novel and efficient method to convert a triflate to a pinacolboronate in large scale.


Research Letters in Organic Chemistry | 2008

A Novel, One-Step Palladium and Phenylsilane Activated Amidation from Allyl Ester on Solid Support

Zheming Ruan; Katy Van Kirk; Christopher B. Cooper; R. Michael Lawrence

The direct conversion of solid-supported carboxylic acid allyl esters to carboxamides through the use of phenylsilane and catalytic Pd(PPh3)4 under mild reaction conditions is reported. The use of this methodology for the generation of a 48 compound solid-phase array is described herein.


Archive | 2004

Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators

Wu Yang; John K. Dickson; Christopher B. Cooper; Dharmpal S. Dodd; Zheming Ruan; Dora M. Schnur

Collaboration


Dive into the Zheming Ruan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge